

November 25, 2014



## **Ebola Patient Who Received Aethlon Hemopurifier® Therapy Has Been Discharged From Hospital**

SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that an Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients.



The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At the time Hemopurifier® therapy was administered to the Ugandan physician, he was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment.

In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against bioterror and pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

### **About Aethlon Medical, Inc.**

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.

Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit <http://www.aethlonmedical.com/> and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#) and [Google+](#).

*Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

Contacts:

Leah-Michelle Nebbia (for interviews requests)

Golin

202-585-2651

[lnebbia@golin.com](mailto:lnebbia@golin.com)

James A. Joyce

Chairman and CEO

(Office) 858.459.7800 x301  
(Cell) 619-368-2000  
[jj@aethlonmedical.com](mailto:jj@aethlonmedical.com)

Jim Frakes  
Chief Financial Officer  
858.459.7800 x300  
[jfrakes@aethlonmedical.com](mailto:jfrakes@aethlonmedical.com)

Photo - <https://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/ebola-patient-who-received-aethlon-hemopurifier-therapy-has-been-discharged-from-hospital-300000853.html>

SOURCE Aethlon Medical, Inc.